Home > D. Systemic pathology > Toxics and drugs > Therapeutics > Targeted therapy > Pathway-targeted therapy > MAPK pathway inhibitors

MAPK pathway inhibitors

Sunday 5 January 2014

MAPK pathway inhibitors

The MAPK pathway is a key therapeutic target for melanoma as it is activated in most tumors. Despite the clinical success of drugs targeting this pathway, their therapeutic efficacy is limited by the development of drug resistance. To develop effective therapies for melanoma, it is critical to uncover the mechanisms of resistance to BRAF inhibitors and MEK inhibitors. Recent studies on the molecular mechanisms of resistance to inhibitors of the MAPK pathway and potential strategies to overcome resistance will be discussed.